Mate I agree that seeing extra dilution is a pain. But the last...

Mate I agree that seeing extra dilution is a pain. But the last CR was needed as the bank balance was getting low.

Good news is that this is the first full quarter with product in the market. Three products for sale in Australia and two for sale in the USA. So as they start to capture market share we should see revenue grow. Which in turn will extend the finance runway. A slow start, but it is now underway.

Also third parties are now starting to pick up the expense of trials, while ZLD get to keep the IP. The last quarter also included start up and storeage expenes pre-release of insomnia and hope into Australia. A lot of this will be one off.

So ZLD really is a low cost based Biotech. I think in one interview Richard talks about it eventually becoming attractive for a buyout. When cannabis medicine becomes more a standard form of care I wouldnt be surprised if that were to happen. But that is still a long way away.